{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:06:59Z","timestamp":1790262419747,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["fertstertreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&S Reports"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.xfre.2022.11.010","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T17:10:04Z","timestamp":1669050604000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S","title":["Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis"],"prefix":"10.1016","volume":"4","author":[{"given":"Juan C.","family":"Arjona Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Migoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xfre.2022.11.010_bib1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMra1810764","volume":"382","author":"Zondervan","year":"2020","journal-title":"Endometriosis. N Engl J Med"},{"key":"10.1016\/j.xfre.2022.11.010_bib2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.xfre.2022.11.010_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-0037-1607264","article-title":"Uterine fibroids: burden and unmet medical need","volume":"35","author":"Al-Hendy","year":"2017","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.xfre.2022.11.010_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.04.023","article-title":"Severe anemia from heavy menstrual bleeding requires heightened attention","volume":"213","author":"Nelson","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.xfre.2022.11.010_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0015-0282(97)81904-8","article-title":"Changing trends in the diagnosis of endometriosis: a comparative study of women with pelvic endometriosis presenting with chronic pelvic pain or infertility","volume":"67","author":"Dmowski","year":"1997","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2022.11.010_bib6","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/AOG.0000000000004401","article-title":"Management of symptomatic uterine leiomyomas: ACOG practice bulletin, Number 228","volume":"137","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfre.2022.11.010_bib7","series-title":"SAT 292-325-Breast & Prostate Cancer","article-title":"Safety and testosterone-lowering effects of the investigational, oral, GnRH antagonist, TAK-385 in healthy male volunteers: results of a phase 1 inpatient\/outpatient study","author":"MacLean","year":"2013"},{"key":"10.1016\/j.xfre.2022.11.010_bib8","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1021\/jm200216q","volume":"54","author":"Miwa","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.xfre.2022.11.010_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2013.12.001","article-title":"Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice","volume":"723","author":"Nakata","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.xfre.2022.11.010_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-019-01105-0","article-title":"Relugolix: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.xfre.2022.11.010_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","article-title":"Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial","volume":"133","author":"Osuga","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfre.2022.11.010_bib12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.fertnstert.2019.07.013","article-title":"Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women","volume":"112","author":"Osuga","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2022.11.010_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.fertnstert.2020.07.055","article-title":"Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose\u2013response manner: a randomized, double-blind, placebo-controlled study","volume":"115","author":"Osuga","year":"2021","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2022.11.010_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2021.11.013","article-title":"Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study","volume":"117","author":"Harada","year":"2022","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2022.11.010_bib15","unstructured":"RELUMINA Prescribing Information.\u00a02021."},{"key":"10.1016\/j.xfre.2022.11.010_bib16","unstructured":"ORGOVYX (relugolix) Prescribing Information. ORGOVYX (relugolix) Prescribing Information, FDA.\u00a02020."},{"key":"10.1016\/j.xfre.2022.11.010_bib17","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/0002-9378(90)90667-V","article-title":"Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis","volume":"163","author":"Friedman","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.xfre.2022.11.010_bib18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/0002-9378(92)91706-G","article-title":"Hormone treatment of endometriosis: the estrogen threshold hypothesis","volume":"166","author":"Barbieri","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.xfre.2022.11.010_bib19","unstructured":"MYFEMBREE Prescribing Information.\u00a02022."},{"key":"10.1016\/j.xfre.2022.11.010_bib20","article-title":"RYEQO (40 mg relugolix, 1 mg estradiol and 0.5 mg norethisterone acetate)","year":"2021","journal-title":"Summary of product characteristics"},{"key":"10.1016\/j.xfre.2022.11.010_bib21","unstructured":"ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov. Accessed August 30, 2022."},{"key":"10.1016\/j.xfre.2022.11.010_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12905-021-01475-2","article-title":"Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial","volume":"21","author":"Hoshiai","year":"2021","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.xfre.2022.11.010_bib23","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.fertnstert.2020.08.248","article-title":"Characterization of pituitary and ovarian hormone concentrations during treatment with relugolix combination therapy","volume":"114","author":"Duijkers","year":"2020","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2022.11.010_bib24","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy [Supplementary Appendix]","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfre.2022.11.010_bib25","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/AOG.0000000000004787","article-title":"Relugolix combination therapy for uterine leiomyoma\u2013associated pain in the LIBERTY randomized trials","volume":"139","author":"Stewart","year":"2022","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfre.2022.11.010_bib26","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/S0140-6736(22)00622-5","article-title":"Relugolix combination therapy in patients with endometriosis pain: two replicate design randomized, double-blind, placebo-controlled phase 3 studies (SPIRIT 1 and SPIRIT 2)","volume":"399","author":"Giudice","year":"2022","journal-title":"Lancet"}],"container-title":["F&S Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334122001210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334122001210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T17:02:34Z","timestamp":1738515754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666334122001210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2666334122001210"],"URL":"https:\/\/doi.org\/10.1016\/j.xfre.2022.11.010","relation":{},"ISSN":["2666-3341"],"issn-type":[{"value":"2666-3341","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis","name":"articletitle","label":"Article Title"},{"value":"F&S Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfre.2022.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}